The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

E. Ilijic; J.N. Guzman; D.J. Surmeier

doi:10.1016/j.nbd.2011.04.007

journal article Aug 01, 2011

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

E. Ilijic J.N. Guzman D.J. Surmeier

Neurobiology of Disease Vol. 43 No. 2 pp. 364-371 · Elsevier BV

View at Publisher Save 10.1016/j.nbd.2011.04.007

Topics

No keywords indexed for this article. Browse by subject →

References

43

[1]

Anekonda "L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease" Neurobiol. Dis. (2011) 10.1016/j.nbd.2010.08.020

[2]

Bean "Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state" Proc Natl Acad Sci USA. (1984) 10.1073/pnas.81.20.6388

[3]

Bean "Multiple types of calcium channels in heart muscle and neurons. Modulation by drugs and neurotransmitters" Ann. N.Y. Acad. Sci. (1989) 10.1111/j.1749-6632.1989.tb24113.x

[4]

Becker "Use of antihypertensives and the risk of Parkinson disease" Neurology (2008) 10.1212/01.wnl.0000303818.38960.44

[5]

Bonci "L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons" J. Neurosci. (1998) 10.1523/jneurosci.18-17-06693.1998

[6]

Bove "Toxin-induced models of Parkinson's disease" NeuroRx. (2005) 10.1602/neurorx.2.3.484

[7]

Chan "'Rejuvenation' protects neurons in mouse models of Parkinson's disease" Nature (2007) 10.1038/nature05865

[8]

Clifton "The pharmacokinetics of oral isradipine in normal volunteers" J. Clin. Pharmacol. (1988) 10.1002/j.1552-4604.1988.tb03098.x

[9]

Eisenberg "Calcium channel blockers: an update" Am. J. Med. (2004) 10.1016/j.amjmed.2003.08.027

[10]

Fitton "Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease" Drugs (1990) 10.2165/00003495-199040010-00004

[11]

Franklin (1997)

[12]

Ganz "Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study" J Clin Hypertens (Greenwich). (2005) 10.1111/j.1524-6175.2005.04450.x

[13]

Gleichmann (2010)

[14]

Gundersen "The efficiency of systematic sampling in stereology and its prediction" J. Microsc. (1987) 10.1111/j.1365-2818.1987.tb02837.x

[15]

Guzman (2010)

[16]

Hirsch "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease" Nature (1988) 10.1038/334345a0

[17]

Huber "Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain" Biochem. J. (2000) 10.1042/0264-6021:3470829

[18]

Johnson "Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals" Prog Neuropsychopharmacol Biol Psychiatry. (2005) 10.1016/j.pnpbp.2004.08.014

[19]

Khaliq "Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances" J. Neurosci. (2010) 10.1523/jneurosci.0143-10.2010

[20]

Kirik "Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat" Exp. Neurol. (1998) 10.1006/exnr.1998.6848

[21]

Kupsch "Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice" Neuroreport (1995) 10.1097/00001756-199503000-00009

[22]

Kupsch "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level" Brain Res. (1996) 10.1016/s0006-8993(96)00917-1

[23]

McCormack "Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat" Neurobiol. Dis. (2002) 10.1006/nbdi.2002.0507

[24]

Mochizuki "Histochemical detection of apoptosis in Parkinson's disease" J. Neurol. Sci. (1996) 10.1016/0022-510x(95)00336-z

[25]

Nelson "Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist" Clin. Pharmacol. Ther. (1986) 10.1038/clpt.1986.246

[26]

Oorschot "Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods" J. Comp. Neurol. (1996) 10.1002/(sici)1096-9861(19960318)366:4<580::aid-cne3>3.0.co;2-0

[27]

Park "Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study" J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2009) 10.1016/j.jchromb.2008.11.021

[28]

Przedborski "MPTP as a mitochondrial neurotoxic model of Parkinson's disease" J. Bioenerg. Biomembr. (2004) 10.1023/b:jobb.0000041771.66775.d5

[29]

Riederer "Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis" J. Neural Transm. (1976) 10.1007/bf01249445

[30]

Ritz "L-type calcium channel blockers and Parkinson disease in Denmark" Ann. Neurol. (2010) 10.1002/ana.21937

[31]

Sauer "Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat" Neuroscience (1994) 10.1016/0306-4522(94)90605-x

[32]

Sautter "Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine" Exp Brain Res. (1997) 10.1007/s002210050204

[33]

Schuster "Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia" Biol. Psychiatry (2009) 10.1016/j.biopsych.2008.09.008

[34]

Shenfield "The pharmokinetics of isradipine in hypertensive subjects" Eur. J. Clin. Pharmacol. (1990) 10.1007/bf00265988

[35]

Simon "Calcium channel blocker use and risk of Parkinson's disease" Mov. Disord. (2010) 10.1002/mds.23191

[36]

Simuni (2010)

[37]

Sinnegger-Brauns "Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms" Mol. Pharmacol. (2009) 10.1124/mol.108.049981

[38]

Surmeier (2010)

[39]

In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining

N.A Tatton, S.J Kish

Neuroscience 1997 10.1016/s0306-4522(96)00545-3

[40]

Uchida "In vivo specific binding characteristics and pharmacokinetics of a 1,4-dihydropyridine calcium channel antagonist in the senescent mouse brain" Pharm. Res. (2000) 10.1023/a:1007512426420

[41]

Vila "Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease" Proc Natl Acad Sci USA. (2001) 10.1073/pnas.051633998

[42]

Vila "Targeting programmed cell death in neurodegenerative diseases" Nat. Rev. Neurosci. (2003) 10.1038/nrn1100

[43]

West "Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator" Anat. Rec. (1991) 10.1002/ar.1092310411

Cited By

227

Isradipine Versus Placebo in Early Parkinson Disease

· 2020

Annals of Internal Medicine

The ongoing pursuit of neuroprotective therapies in Parkinson disease

Dilan Athauda, Thomas Foltynie · 2014

Nature Reviews Neurology

Metrics

227

Citations

43

References

Details

Published: Aug 01, 2011
Vol/Issue: 43(2)
Pages: 364-371
License: View

Authors

Cite This Article

E. Ilijic, J.N. Guzman, D.J. Surmeier (2011). The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiology of Disease, 43(2), 364-371. https://doi.org/10.1016/j.nbd.2011.04.007

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

You May Also Like